Cargando…
Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy
BACKGROUND: Our intention was to compare the rate of immunological progression prior to antiretroviral therapy (ART) and the virological response to ART in patients infected with subtype B and four non-B HIV-1 subtypes (A, C, D and the circulating recombinant form, CRF02-AG) in an ethnically diverse...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The International AIDS Society
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827379/ https://www.ncbi.nlm.nih.gov/pubmed/20205896 http://dx.doi.org/10.1186/1758-2652-13-4 |
_version_ | 1782177930590289920 |
---|---|
author | Easterbrook, Philippa J Smith, Mel Mullen, Jane O'Shea, Siobhan Chrystie, Ian de Ruiter, Annemiek Tatt, Iain D Geretti, Anna Maria Zuckerman, Mark |
author_facet | Easterbrook, Philippa J Smith, Mel Mullen, Jane O'Shea, Siobhan Chrystie, Ian de Ruiter, Annemiek Tatt, Iain D Geretti, Anna Maria Zuckerman, Mark |
author_sort | Easterbrook, Philippa J |
collection | PubMed |
description | BACKGROUND: Our intention was to compare the rate of immunological progression prior to antiretroviral therapy (ART) and the virological response to ART in patients infected with subtype B and four non-B HIV-1 subtypes (A, C, D and the circulating recombinant form, CRF02-AG) in an ethnically diverse population of HIV-1-infected patients in south London. METHODS: A random sample of 861 HIV-1-infected patients attending HIV clinics at King's and St Thomas' hospitals' were subtyped using an in-house enzyme-linked immunoassay and env sequencing. Subtypes were compared on the rate of CD4 cell decline using a multi-level random effects model. Virological response to ART was compared using the time to virological suppression (< 400 copies/ml) and rate of virological rebound (> 400 copies/ml) following initial suppression. RESULTS: Complete subtype and epidemiological data were available for 679 patients, of whom 357 (52.6%) were white and 230 (33.9%) were black African. Subtype B (n = 394) accounted for the majority of infections, followed by subtypes C (n = 125), A (n = 84), D (n = 51) and CRF02-AG (n = 25). There were no significant differences in rate of CD4 cell decline, initial response to highly active antiretroviral therapy and subsequent rate of virological rebound for subtypes B, A, C and CRF02-AG. However, a statistically significant four-fold faster rate of CD4 decline (after adjustment for gender, ethnicity and baseline CD4 count) was observed for subtype D. In addition, subtype D infections showed a higher rate of virological rebound at six months (70%) compared with subtypes B (45%, p = 0.02), A (35%, p = 0.004) and C (34%, p = 0.01) CONCLUSIONS: This is the first study from an industrialized country to show a faster CD4 cell decline and higher rate of subsequent virological failure with subtype D infection. Further studies are needed to identify the molecular mechanisms responsible for the greater virulence of subtype D. |
format | Text |
id | pubmed-2827379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | The International AIDS Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-28273792010-02-24 Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy Easterbrook, Philippa J Smith, Mel Mullen, Jane O'Shea, Siobhan Chrystie, Ian de Ruiter, Annemiek Tatt, Iain D Geretti, Anna Maria Zuckerman, Mark J Int AIDS Soc Research BACKGROUND: Our intention was to compare the rate of immunological progression prior to antiretroviral therapy (ART) and the virological response to ART in patients infected with subtype B and four non-B HIV-1 subtypes (A, C, D and the circulating recombinant form, CRF02-AG) in an ethnically diverse population of HIV-1-infected patients in south London. METHODS: A random sample of 861 HIV-1-infected patients attending HIV clinics at King's and St Thomas' hospitals' were subtyped using an in-house enzyme-linked immunoassay and env sequencing. Subtypes were compared on the rate of CD4 cell decline using a multi-level random effects model. Virological response to ART was compared using the time to virological suppression (< 400 copies/ml) and rate of virological rebound (> 400 copies/ml) following initial suppression. RESULTS: Complete subtype and epidemiological data were available for 679 patients, of whom 357 (52.6%) were white and 230 (33.9%) were black African. Subtype B (n = 394) accounted for the majority of infections, followed by subtypes C (n = 125), A (n = 84), D (n = 51) and CRF02-AG (n = 25). There were no significant differences in rate of CD4 cell decline, initial response to highly active antiretroviral therapy and subsequent rate of virological rebound for subtypes B, A, C and CRF02-AG. However, a statistically significant four-fold faster rate of CD4 decline (after adjustment for gender, ethnicity and baseline CD4 count) was observed for subtype D. In addition, subtype D infections showed a higher rate of virological rebound at six months (70%) compared with subtypes B (45%, p = 0.02), A (35%, p = 0.004) and C (34%, p = 0.01) CONCLUSIONS: This is the first study from an industrialized country to show a faster CD4 cell decline and higher rate of subsequent virological failure with subtype D infection. Further studies are needed to identify the molecular mechanisms responsible for the greater virulence of subtype D. The International AIDS Society 2010-02-03 /pmc/articles/PMC2827379/ /pubmed/20205896 http://dx.doi.org/10.1186/1758-2652-13-4 Text en Copyright ©2010 Easterbrook et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Easterbrook, Philippa J Smith, Mel Mullen, Jane O'Shea, Siobhan Chrystie, Ian de Ruiter, Annemiek Tatt, Iain D Geretti, Anna Maria Zuckerman, Mark Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy |
title | Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy |
title_full | Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy |
title_fullStr | Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy |
title_full_unstemmed | Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy |
title_short | Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy |
title_sort | impact of hiv-1 viral subtype on disease progression and response to antiretroviral therapy |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827379/ https://www.ncbi.nlm.nih.gov/pubmed/20205896 http://dx.doi.org/10.1186/1758-2652-13-4 |
work_keys_str_mv | AT easterbrookphilippaj impactofhiv1viralsubtypeondiseaseprogressionandresponsetoantiretroviraltherapy AT smithmel impactofhiv1viralsubtypeondiseaseprogressionandresponsetoantiretroviraltherapy AT mullenjane impactofhiv1viralsubtypeondiseaseprogressionandresponsetoantiretroviraltherapy AT osheasiobhan impactofhiv1viralsubtypeondiseaseprogressionandresponsetoantiretroviraltherapy AT chrystieian impactofhiv1viralsubtypeondiseaseprogressionandresponsetoantiretroviraltherapy AT deruiterannemiek impactofhiv1viralsubtypeondiseaseprogressionandresponsetoantiretroviraltherapy AT tattiaind impactofhiv1viralsubtypeondiseaseprogressionandresponsetoantiretroviraltherapy AT gerettiannamaria impactofhiv1viralsubtypeondiseaseprogressionandresponsetoantiretroviraltherapy AT zuckermanmark impactofhiv1viralsubtypeondiseaseprogressionandresponsetoantiretroviraltherapy |